What’s in Infinity Pharmaceuticals, Inc. (INFI) After Today’s Huge Increase?

March 14, 2018 - By Adrian Erickson

Investors sentiment decreased to 0.47 in 2017 Q3. Its down 0.16, from 0.63 in 2017Q2. It dived, as 15 investors sold Infinity Pharmaceuticals, Inc. shares while 23 reduced holdings. 6 funds opened positions while 12 raised stakes. 27.30 million shares or 18.05% less from 33.31 million shares in 2017Q2 were reported.
Federated Pa, a Pennsylvania-based fund reported 3,876 shares. Aperio Group Inc Ltd Liability Com, California-based fund reported 11,161 shares. Royal Comml Bank Of Canada stated it has 1,500 shares or 0% of all its holdings. Bancorp Of Ny Mellon has 0% invested in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) for 45,985 shares. Rock Springs Management Limited Partnership has invested 0.02% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Morgan Stanley owns 84,370 shares. State Street invested in 0% or 67,405 shares. Citadel Lc accumulated 0% or 10,590 shares. Bnp Paribas Arbitrage reported 0% of its portfolio in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Vanguard Grp, Pennsylvania-based fund reported 2.35M shares. Wells Fargo & Communication Mn reported 13,930 shares or 0% of all its holdings. Platinum Invest Ltd has 1.41M shares. Meeder Asset Management, Ohio-based fund reported 2,638 shares. Blackrock Inc holds 1.01 million shares. D E Shaw & accumulated 421,544 shares.

Since October 3, 2017, it had 1 buy, and 1 insider sale for $1.99 million activity. 5,000 shares were sold by Perkins Adelene Q, worth $13,890 on Monday, March 5.

The stock of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) is a huge mover today! The stock increased 8.91% or $0.22 during the last trading session, reaching $2.69. About 1.14M shares traded or 41.93% up from the average. Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) has declined 60.96% since March 14, 2017 and is downtrending. It has underperformed by 77.66% the S&P500.
The move comes after 7 months positive chart setup for the $136.41 million company. It was reported on Mar, 14 by Barchart.com. We have $2.77 PT which if reached, will make NASDAQ:INFI worth $4.09M more.

Analysts await Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) to report earnings on March, 15 after the close. They expect $-0.27 EPS, up 41.30 % or $0.19 from last year’s $-0.46 per share. After $-0.14 actual EPS reported by Infinity Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 92.86 % negative EPS growth.

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Ratings Coverage

Among 9 analysts covering Infinity Pharmaceutical (NASDAQ:INFI), 2 have Buy rating, 0 Sell and 7 Hold. Therefore 22% are positive. Infinity Pharmaceutical had 16 analyst reports since August 7, 2015 according to SRatingsIntel. Wells Fargo upgraded the stock to “Outperform” rating in Thursday, October 12 report. The rating was initiated by FBR Capital with “Outperform” on Wednesday, March 2. The firm has “Equal-Weight” rating by Morgan Stanley given on Wednesday, June 15. The rating was upgraded by Wedbush on Tuesday, June 14 to “Neutral”. The company was maintained on Friday, August 7 by RBC Capital Markets. The rating was downgraded by Wells Fargo to “Market Perform” on Wednesday, June 15. The firm earned “Hold” rating on Monday, August 10 by Zacks. The firm has “Neutral” rating given on Thursday, February 25 by Wedbush. The stock of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) has “Overweight” rating given on Monday, September 21 by Morgan Stanley. The company was downgraded on Tuesday, June 14 by .

Another recent and important Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) news was published by Prnewswire.com which published an article titled: “Infinity Pharmaceuticals Announces Additions to Board of Directors and …” on March 08, 2018.

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. The company has market cap of $136.41 million. The Company’s lead product candidate includes IPI-549 an orally administered immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma is in Phase 1 clinical study. It currently has negative earnings. The firm has a license agreement with Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib, a selective inhibitor of the PI3K delta and gamma isoforms, including DUO study that is in randomized Phase III clinical study for patients with relapsed/refractory chronic lymphocytic leukemia and products containing duvelisib; Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; and Takeda Pharmaceutical Company Limited to develop and commercialize duvelisib.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.